MediciNova, Inc.
NASDAQ:MNOVBiotechnology
Healthcare
$1.27 -1.32%
-$0.02 today
- Market cap
- $65.07M
- Beta
- 0.62
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.24
52W Low $1.17High $1.96
Volume 0.09M
Average 0.04M
Income Statement
Follow revenue through to earnings.
Revenue
$409,657.00
FY 2025 · Annual
Operating Income
-$13.28M
FY 2025 · Annual
Net Income
-$12.00M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.04M | 0 | 1M | 0 | 409.66K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 378.61K |
| Gross Profit | 4.04M | 0 | 1M | 0 | 31.05K |
| Gross Margin | 100.0% | — | 100.0% | — | 7.6% |
| Research & Development | 8.1M | 9.14M | 5.66M | 7.2M | 7.15M |
| Selling, General & Admin | 5.72M | 5.48M | 5.24M | 5.48M | 6.16M |
| Operating Expenses | 14.25M | 14.63M | 10.9M | 12.68M | 13.31M |
| Depreciation & Amortization | 26.15K | 17.71K | 20.3K | 21.08K | 20.1K |
| EBITDA | (10.11M) | (14.05M) | (8.55M) | (11.02M) | (11.97M) |
| EBITDA Margin | -250.3% | — | -854.8% | — | -2922.4% |
| Operating Income | (10.22M) | (14.63M) | (9.9M) | (12.68M) | (13.28M) |
| Operating Margin | -253.0% | — | -990.0% | — | -3242.5% |
| Interest Income | 143.63K | 809.67K | 1.83M | 1.67M | 1.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 84.13K | 562.39K | 1.33M | 1.63M | 1.29M |
| Income Before Tax | (10.13M) | (14.07M) | (8.57M) | (11.04M) | (11.99M) |
| Pre-Tax Margin | -250.9% | — | -856.8% | — | -2927.3% |
| Income Tax Expense | 2.57K | 2.82K | 3.05K | 5.54K | 5.99K |
| Net Income | (10.13M) | (14.07M) | (8.57M) | (11.05M) | (12M) |
| Net Margin | -251.0% | — | -857.2% | — | -2928.8% |
| EPS (Basic) | (0.21) | (0.29) | (0.17) | (0.23) | (0.24) |
| EPS (Diluted) | (0.21) | (0.29) | (0.17) | (0.23) | (0.24) |
| 48.6M | 49.05M | 49.05M | 49.05M | 49.06M | |
| 48.6M | 49.05M | 49.05M | 49.05M | 49.06M |
MNOV Earnings Waterfall · TTM
NASDAQ:MNOV · Revenue to Net Income
Key Ratios
EPS$-0.23
Gross Margin15.2%
Net Margin-2035.3%
P/E Ratio-5.6
P/S Ratio441.7
Analysis
$596.6K of revenue converted into -$11.7M of net income for the selected period. Gross margin is 15.2% and net margin is -2035.3%, showing how much revenue survives after costs and taxes. EPS is $-0.23, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 29, 2026 | |
| SC 13D/A | SC 13D/A filing | Sep 29, 2026 | |
| 8-K | Current report | Sep 28, 2026 |
How much revenue does MNOV generate?
MediciNova, Inc. (MNOV) reported $409,657.00 of revenue in fiscal 2025.
Is MNOV profitable?
MediciNova, Inc. (MNOV) reported -$12.00M of net income, with a net margin of -2928.8%.
Continue the stock analysis
Jump to another research area for this company.